Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)

Launched by GUANGZHOU BURNING ROCK DX CO., LTD. · Jan 26, 2022

Keywords

ClinConnect Summary

The PREVENT trial is studying a new blood test called the OverC multi-cancer detection test, which aims to find early signs of cancer in people who do not currently have any symptoms. This study is looking for participants who are between 40 and 75 years old and who have not had certain cancer screening tests, like colonoscopies or CT scans, in the past five years. To join, individuals need to be able to give a blood sample and provide written consent to participate.

If you qualify and choose to take part in this trial, you will have your blood tested to see how well the OverC test can detect cancer early. The study is currently recruiting participants of all genders, and it’s important to note that certain health conditions or recent medical procedures may prevent someone from joining. This trial represents an exciting opportunity to contribute to research that could improve how we detect cancer before symptoms appear.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must be able to provide a written informed consent form
• • Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form
• • Participants must be able to provide blood samples for study tests
• • Participants must be between 40 and 75 years old
• Exclusion Criteria:
• • Individuals who have an acute infection or inflammation within 14 days prior to recruitment
• • Individuals with cancer-associated clinical symptoms or suspected of cancer
• • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
• • Recipient of blood transfusion within 7 days prior to recruitment
• • Individuals who have pure ground-glass opacity
• • Unable to provide blood samples for the multi-cancer early detection blood test
• • Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests
• • Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment
• • Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment
• • Individuals with hemorrhagic diseases
• • Individuals with autoimmune diseases
• • Individuals who are pregnant or lactating
• • Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers